Expression of CD24, p21, p53, and c-myc in alpha-fetoprotein-producing gastric cancer: Correlation with clinicopathologic characteristics and survival

Journal of Surgical Oncology

Volumn 109, Issue 8, 2014, Pages 859-864

  Liu, Xiaowen ^a,b   Yu, Hongmei ^a,b   Cai, Hong ^a,b   Wang, Yanong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

alpha fetoprotein producing gastric cancer; c myc; CD24; p21; p53

Indexed keywords

ALPHA FETOPROTEIN; CD24 ANTIGEN; MYC PROTEIN; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER; TUMOR INVASION;

ALPHA-FETOPROTEIN-PRODUCING GASTRIC CANCER; C-MYC; CD24; P21; P53;

ADENOCARCINOMA; ALPHA-FETOPROTEINS; ANTIGENS, CD24; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900538332     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23599     Document Type: Article

References (40)

1. Bourreille J, Metayer P, Sauger F, et al.: Existence of alpha feto protein during gastric-origin secondary cancer of the liver. Presse Med 1970; 78: 1277-1278.
2. Kono K, Amemiya H, Sekikawa T, et al.: Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 2002; 19: 359-365; discussion 365.
3. Chang YC, Nagasue N, Kohno H, et al.: Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol 1990; 85: 1480-1485.
4. Liu X, Cheng Y, Sheng W, et al.: Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: Analysis of 104 cases. J Surg Oncol 2010; 102: 249-255. doi: 10.1002/jso.21624
5. Adachi Y, Tsuchihashi J, Shiraishi N, et al.: AFP-producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients. Oncology 2003; 65: 95-101.
6. Chun H, Kwon SJ:, Clinicopathological characteristics of alpha-fetoprotein-produc- Ing gastric cancer. J Gastric Cancer. 2011; 11: 23-30. doi: 10.5230/jgc.2011.11.1.23 Epub2011 Mar 31.
7. Pirruccello SJ, LeBien TW:, The human B cell-associated antigen CD24 is a single chain sialoglycoprotein. J Immunol 1986; 136: 3779-3784.
8. Fischer GF, Majdic O, Gadd S, et al.: Signal transduction in lymphocytic and myeloid cells via CD24, a new member of phosphoinositol-anchored membrane molecules. J Immunol 1990; 144: 638-641.
9. Elghetany MT, Patel J:, Assessment of CD24 expression on bone marrow neutrophilic granulocytes: CD24 is a marker for the myelocytic stage of development. Am J Hematol 2002; 71: 348-349.
10. Magnaldo T, Barrandon Y:, CD24 (heat stable antigen, nectadrin), a novel keratinocyte differentiation marker, is preferentially expressed in areas of the hair follicle containing the colony-forming cells. J Cell Sci 1996; 109: 3035-3045.
11. Suzuki T, Kiyokawa N, Taguchi T, et al.: CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001; 166: 5567-5577.
12. Figarella-Branger D, Moreau H, Pellissier JF, et al.: CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle. Acta Neuropathol 1993; 86: 275-284.
13. Ahmed MA, Al-Attar A, Kim J, et al.: CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer. J Clin Pathol 2009; 62: 1117-1122. doi: 10.1136/jcp.2009.069310
14. Chou YY, Jeng YM, Lee TT, et al.: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007; 14: 2748-2758. Epub 2007 Aug 7.
15. Kristiansen G, Pilarsky C, Pervan J, et al.: CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004; 58: 183-192.
16. Ford HL, Sclafani RA, DeGregori J:, Cell cycle and growth control. Biomolecular regulation and cancer. In:, Stein GSaP AB, editor. Cell cycle regulatory cascades, Hoboken, New Jersey: Wiley-Liss. 2004. pp. 95-128.
17. Zhang H, Fang DC, Wang RQ, et al.: Effect of Helicobacter pylori infection on expression of Bcl-2 family members in gastric adenocarcinoma. World J Gastroenterol 2004; 10: 227-230.
18. Sobin LH, Wittekind CH, editors. TNM: Classification of malignant tumours, 6th edition. New York: Wiley-Liss; 2002.
19. Liu X, Cai H, Huang H, et al.: The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS ONE 2011; 6: e29670.
20. Cho YG, Song JH, Kim CJ, et al.: Genetic alterations of the ATBF1 gene in gastric cancer. Clin Cancer Res 2007; 13: 4355-4359.
21. Kinjo T, Taniguchi H, Kushima R, et al.: Histologic and immunohistochemical analyses of α-fetoprotein-producing cancer of the stomach. Am J Surg Pathol 2012; 36: 56-65. doi: 10.1097/PAS.0b013e31823aafec
22. Friederichs J, Zeller Y, Hafezi-Moghadam A, et al.: The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000; 60: 6714-6722.
23. Darwish NS, Kim MA, Chang MS, et al.: Prognostic significance of CD24 expression in gastric carcinoma. Cancer Res Treat 2004; 36: 298-302. doi: 10.4143/crt.2004.36.5.298 Epub2004 Oct 30.
24. LaBaer J, Garrett MD, Stevenson LF, et al.: New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997; 11: 847-862.
25. Abbas T, Dutta A:, p21 in cancer: Intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414. doi: 10.1038/nrc2657
26. Mizokami K, Kakeji Y, Oda S, et al.: Relationship of hypoxia-inducible factor 1alpha and p21WAF1/CIP1 expression to cell apoptosis and clinical outcome in patients with gastric cancer. World J Surg Oncol 2006; 4: 94.
27. Mattioli E, Vogiatzi P, Sun A, et al.: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol 2007; 210: 183-191.
28. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, et al.: Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol 2007; 60: 756-761. Epub 2007 May 4.
29. Kouraklis G, Katsoulis IE, Theocharis S, et al.: Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma ? Dig Dis Sci 2009; 54: 1015-1020. doi: 10.1007/s10620-008-0464-y Epub2008 Dec 5.
30. Ozen A, Kocak Z, Sipahi T, et al.: The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Med Oncol 2013; 30: 357. doi: 10.1007/s12032-012-0357-y Epub2012 Dec 29.
31. Gunia S, Kakies C, Erbersdobler A, et al.: Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. J Clin Pathol 2012; 65: 232-236. doi: 10.1136/jclinpath-2011-200429 Epub 2011.
32. Ogino S, Kawasaki T, Kirkner GJ, et al.: Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006; 210: 147-154.
33. Aoyagi K, Koufuji K, Yano S, et al.: The expression of p53 p21 TGF beta 1 in gastric carcinoma. Kurume Med J 2003; 50: 1-7.
34. Ping B, He X, Xia W, et al.: Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. Int J Oncol 2006; 29: 1103-1110.
35. Ohata M, Nakamura S, Fujita H, et al.: Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma. Biomed Res 2005; 26: 91-98.
36. Maehara Y, Okuyama T, Kakeji Y, et al.: A tumor-associated cell-surface glycoprotein accompanying p53 over-expression and higher growth potential for gastric cancer. Br J Cancer 1995; 71: 999-1002.
37. Maehara Y, Tomoda M, Hasuda S, et al.: Prognostic value of p53 protein expression for patients with gastric cancer-multivariate analysis. Br J Cancer 1999; 79: 1255-1261.
38. Motojima K, Furui J, Kohara N, et al.: Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 1994; 116: 890-895.
39. Gabbert HE, Muller W, Schneiders A, et al.: The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76: 720-726.
40. Ninomiya I, Yonemura Y, Matsumoto H, et al.: Expression of c-myc gene product in gastric carcinoma. Oncology 1991; 48: 149-153.